Nawsherwan Mohammad: Exploring Thrombophilia in 2026
Nawsherwan Mohammad, Consultant Hematopathologist at Nanakaly Hospital, shared a post on LinkedIn:
“Thrombophilia in 2026
The modern approach to thrombophilia emphasizes precision medicine, recommending selective testing only when the results are likely to influence clinical management.
Testing is appropriate for patients with unprovoked or recurrent VTE, thrombosis at unusual sites, recurrent pregnancy loss, a strong family history, or suspected antiphospholipid syndrome, while it is generally not recommended for provoked VTE, during acute thrombosis or anticoagulation, or as routine screening of relatives.
Current evaluation focuses on high-yield tests, including Factor V Leiden, Prothrombin G20210A, antithrombin, protein C and protein S deficiencies, and antiphospholipid antibodies.
Treatment decisions should be based primarily on the patient’s clinical risk rather than thrombophilia status alone.
High-risk thrombophilias often require specialist care and extended anticoagulation, while emerging evidence supports the use of DOACs in selected patients.
Special populations, particularly pregnant women and patients with antithrombin deficiency, require individualized risk assessment and multidisciplinary management.
Overall, thrombophilia testing should be purpose-driven, evidence-based, and tailored to improve patient outcomes rather than performed routinely.”
Stay updated with Hemosyasis Today.
-
Jul 5, 2026, 19:35Luise Erpenbeck: When Immune Cells Speak the Language of Neurons
-
Jul 5, 2026, 19:14Mubariz Ahsan: Bringing Stroke Research to a Wider Audience
-
Jul 5, 2026, 18:58Linda Hayes Bennett: Redefining Ferroptosis in Aging and Neurodegenerative Conditions
-
Jul 5, 2026, 18:20LV Aneurysm, Thrombus, and Embolism: A Silent Post-MI Threat – Abdallah Othman
-
Jul 5, 2026, 17:58Andaleb Kholmukhamedov: What’s the Most Unusual “False Positive” Trigger You’ve Seen Elevate a D-Dimer?
-
Jul 5, 2026, 17:47Michiel Coppens: Supporting Better Hemophilia Care in Suriname
-
Jul 5, 2026, 17:31Arrigo Francesco Giuseppe Cicero: Redefining the Role of Urate-Lowering Therapy in Cardiovascular Disease
-
Jul 5, 2026, 17:20Ahmad Gharehbaghian: Iranian Blood Transfusion Organization Engages Government Leaders on Blood Service Investment
-
Jul 5, 2026, 17:03Paolo Zamboni։ New Findings Highlight PLXND1 as a Critical Mechanosensor in Primary Lymphedema